Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
Dana Farber/Massachusetts General Hospital, Inc, Boston, Massachusetts SCRI Lake Mary, Nashville, Tennessee SCRI Oncology Partners, Nashville, Tennessee New Experimental Therapeutics of San Antonio LLC, San Antonio, Texas START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas START Mountain Region, West Valley City, Utah NEXT Virginia, Fairfax, Virginia